Literature DB >> 9680042

Follow-up on the treatment of panic disorder with or without agoraphobia: a quantitative review.

A Bakker1, A J van Balkom, P Spinhoven, B M Blaauw, R van Dyck.   

Abstract

We conducted a meta-analysis to update the knowledge of long-term efficacy of different treatments in panic disorder with or without agoraphobia. Included were 68 studies pertaining to 106 treatment conditions and 1346 patients. Effect sizes Cohen's d were calculated within the treatment conditions at posttest and at follow-up for panic and agoraphobia. A comparison was made between six treatments: high-potency benzodiazepines, antidepressants, psychological panic management, exposure in vivo, antidepressants combined with exposure, and psychological panic management combined with exposure in vivo. The mean (+/- SD) duration of the follow-up period was 62 +/- 89 weeks. In the majority of the studies (84%), follow-up had a naturalistic character. The lack of information about treatments received between posttest and follow-up limits the interpretation of the results. For all conditions, the treatment gains at posttest were maintained during the follow-up period. The mean (+/- SD) d for panic was 1.11 +/- 0.70 at posttest and 1.28 +/- 0.61 at follow-up; for agoraphobia, the mean d at posttest was 1.36 +/- 1.10 and at follow-up it was 1.41 +/- 0.82. Significant differences were found in efficacy on agoraphobic measures at follow-up between the combination of antidepressants and exposure in vivo versus psychological panic management, exposure in vivo, and the combination of psychological panic management and exposure. Overall, the data suggest that different treatment options for panic disorder with or without agoraphobia are effective at both posttest and follow-up. Research on long-term treatment, discontinuation of therapies, and interventions between posttest and follow-up need more attention, for pharmacotherapy as well as psychotherapy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9680042     DOI: 10.1097/00005053-199807000-00005

Source DB:  PubMed          Journal:  J Nerv Ment Dis        ISSN: 0022-3018            Impact factor:   2.254


  6 in total

1.  One-year follow-up of cognitive behavioral therapy for phobic postural vertigo.

Authors:  Johan Holmberg; Mikael Karlberg; Uwe Harlacher; Måns Magnusson
Journal:  J Neurol       Date:  2007-08-03       Impact factor: 4.849

2.  Treatment of anxiety disorders in primary care practice: a randomised controlled trial.

Authors:  Christine A van Boeijen; Patricia van Oppen; Anton J L M van Balkom; Sako Visser; Pieter T Kempe; Nettie Blankenstein; Richard van Dyck
Journal:  Br J Gen Pract       Date:  2005-10       Impact factor: 5.386

3.  Overcoming barriers to disseminating exposure therapies for anxiety disorders: a pilot randomized controlled trial of training methods.

Authors:  Melanie S Harned; Linda A Dimeff; Eric A Woodcock; Julie M Skutch
Journal:  J Anxiety Disord       Date:  2011-03

4.  The effect of doxapram on brain imaging in patients with panic disorder.

Authors:  Amir Garakani; Monte S Buchsbaum; Randall E Newmark; Chelain Goodman; Cindy J Aaronson; Jose M Martinez; Yuliya Torosjan; King-Wai Chu; Jack M Gorman
Journal:  Eur Neuropsychopharmacol       Date:  2007-06-08       Impact factor: 4.600

Review 5.  Diagnosis and treatment of agoraphobia with panic disorder.

Authors:  Giulio Perugi; Franco Frare; Cristina Toni
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

6.  Nonpharmacological treatments for anxiety disorders.

Authors:  Jean Cottraux
Journal:  Dialogues Clin Neurosci       Date:  2002-09       Impact factor: 5.986

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.